Identifying genetic and environmental influences on proteins associated with age, cardiovascular risk, and other endpoints using the SomaScan® Assay


Protein quantitative trait locus (pQTL) studies identify genetic variants that are statistically associated with protein levels. Results from the growing number of pQTL studies can be combined with genome-wide association studies to identify proteins that underlie the genetic risk of disease, thus revealing the mechanisms of disease and potential drug targets.

The SomaScan® Assay is a highly multiplex protein assay that has facilitated the growth in pQTL studies. For affinity-based assays like SomaScan®, cis-pQTLs provide evidence of specificity. However, a pQTL association will only be identified for a given protein if enough of the variation in the protein is due to genetics. Non-genetic sources of variation, such as differences in lifestyle or exposure to environmental risk factors, also influence the risk of disease and can be captured by proteomics.


  • Compiled a list of cis-pQTLs from two studies:
    • 35,559 Icelanders in deCODE1
    • 7,213 European Americans and 1,871 African Americans in ARIC2
  • Calculated proportion of SomaScan® Assay aptamers with cis-pQTLs
  • Compared to proportion of aptamers with cis-pQTLs that are also strongly associated (FDR < 10%) with age, four-year cardiovascular disease risk (CVD), and oral glucose tolerance tests3,4
  • Based on the SomaScan® v4 Assay, which measures ~5,000 proteins


  • The cumulative proportion of analytes that have a cis-pQTL decreases with progressively decreasing significance of association with three endpoints.
  • Regardless of cis-pQTL status, each endpoint is associated (FDR < 10%) with a unique combination of analytes.
  • pQTL association status (FDR < 10%), stratified by respective endpoint association. pQTLs are over-represented in endpoint association, but up to 40% of associated, measured proteins do not have pQTLs. Endpoint associations and pQTLs were identified using a 5K analyte assay, rather than the current 7K analyte assay.


  • Endpoint-associated analytes are more likely to have a cis-pQTL than non-endpoint-associated analytes.
  • Many endpoint-associated analytes do not have a cis-pQTL, indicating potential sensitivity to environmental effects
  • Distinct sets of analytes respond to each endpoint.
  • The SomaScan® Assay is highly multiplex and can identify hundreds to thousands of proteins associated with endpoints and with genetic variants.


Brendan Epstein
Tina Lai
Ted Johnson
Michael A. Hinterberg
David P. Astling

SomaLogic Operating Co., Inc., Boulder, CO USA


  1. Ferkingstad E, et al. Large-scale integration of the plasma proteome with genetics and disease. Nature Genetics 53.12 (2021):1712-1721.
  2. Zhang J, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nature Genetics 54.5 (2022): 593-602.
  3. Williams S, et al. Plasma protein patterns as comprehensive indicators of health. Nature Medicine 25.12 (2019): 1851-1857.

Share with colleagues

More posters

PosterUtility of proteomic trajectories of cardiovascular risk and cardiorespiratory fitness to monitor adverse health states throughout post-COVID-19 illness

Cardiovascular involvement is a prominent observation in patients during the acute phase of COVID-19 infection, as well as in convalescence. However, the etiology, trajectory, and underlying biology of cardiac dysfunction across the spectrum of COVID-19 illness is not fully understood. To address this, the CISCO-19 study (NCT04403607) was formed to investigate the multisystem effects of COVID-19 from hospitalized patients

Learn more

PosterSomaScan® Platform confirmation and performance validation

The SomaScan® Platform for proteomic profiling uses 7288 (7K) SOMAmer® reagents, single stranded DNA aptamers, to 6596 unique Human Protein Targets. The modified aptamer binding reagents1, SomaScan assay2, its performance characteristic for 5k3 and 7k4 content sets, and specificity5,6,7 to human targets have been previously described. We combine profiles of validation and performance metrics with orthogonal confirmation of specificity from published literature to provide a comprehensive view of the specificity and utility of the SomaScan Platform.

Learn more

PosterAptamer-based analysis of plasma proteome of growing tumors 

With proteins, the presence of a tumor is more often accompanied with changes in the levels of endogenous, unmutated proteins in circulation. In this context, knowing which proteins represent the earliest markers or tumor presence would be enormously useful.

Learn more

Explore posters in our interactive viewer